False Positive Paradox (Medical)

The false positive paradox occurs when a test with high accuracy still produces more false positives than true positives when the disease being tested for is rare in the population. Even a test that is 99% accurate can be misleading if the condition affects only 0.1% of people — the majority of positive results can be false alarms. This is a direct consequence of base rate fallacy, where people ignore prevalence and focus only on test accuracy.

Modern HIV tests have sensitivity and specificity both exceeding 99%. However, in a low-prevalence population (e.g. 0.1% prevalence), as few as 9–10% of positive results may actually be true positives — meaning around 90% could be false positives. In higher-prevalence populations (e.g. 1–5%), the PPV rises dramatically. This is why confirmatory testing is always recommended after an initial positive result.

PPV is the probability that a person who tests positive actually has the disease. Using Bayes' theorem: PPV = (Sensitivity × Prevalence) / [(Sensitivity × Prevalence) + (1 − Specificity) × (1 − Prevalence)]. It depends not just on test accuracy but critically on the base rate (prevalence) of the disease in the tested population.

Sensitivity = True Positives / (True Positives + False Negatives) — it measures how well a test detects people who actually have the disease. Specificity = True Negatives / (True Negatives + False Positives) — it measures how well a test correctly rules out people without the disease. Both are properties of the test itself and do not depend on prevalence.

NPV is the probability that a person who tests negative truly does not have the disease. It is calculated as: NPV = (Specificity × (1 − Prevalence)) / [(Specificity × (1 − Prevalence)) + (1 − Sensitivity) × Prevalence]. In low-prevalence diseases, NPV tends to be very high, meaning a negative test is very reassuring.

A classic example: a doctor tells a patient they tested positive for a rare disease affecting 1 in 1,000 people, using a test that is 99% accurate. Most people — and even many doctors — assume there's a 99% chance the patient has the disease. In reality, because the disease is so rare, the true probability may be closer to 9%, because the number of false positives vastly outnumbers true positives. Ignoring the low prevalence (base rate) is the base rate fallacy.

Two main strategies help: (1) Use confirmatory testing — if an initial positive result is followed by a second independent test, the combined probability of being a true positive rises dramatically. (2) Screen higher-risk populations — targeting testing at groups with higher prevalence raises the base rate and therefore the PPV, making positive results more meaningful and reducing false positive rates.

Even with a highly specific test, when a disease is very rare, the number of healthy people who test false-positive can greatly exceed the number of truly sick people who test true-positive. For example, testing 1,000,000 people where only 100 have a disease — even a 99% specific test will incorrectly flag ~9,999 healthy people as positive, swamping the 99 true positives. Prevalence is the hidden lever that drives PPV.